Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours
- PMID: 20088918
- PMCID: PMC3082427
- DOI: 10.1111/j.1365-2354.2009.01121.x
Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours
Abstract
Chemotherapy-induced neutropenia, the major dose-limiting toxicity of chemotherapy, is directly associated with concomitant morbidity, mortality and health-care costs. The use of prophylactic granulocyte colony-stimulating factors may reduce the incidence and duration of chemotherapy-induced neutropenia, and is recommended in high-risk patients. The objective of this study was to develop a model to predict first-cycle chemotherapy-induced neutropenia (defined as neutropenia grade>or=3, with or without body temperature>or=38 degrees C) in patients with solid tumours. A total of 1194 patients [56% women; mean age 58+/-12 years; 94% Eastern Cooperative Oncology Group (ECOG) status<or=1] with solid tumours were included in a multi-centre non-interventional prospective cohort study. A predictive logistic regression model was developed. Several factors were found to influence chemotherapy-induced neutropenia. Higher ECOG status values increased toxicity (ECOG 2 vs. 0, P=0.003; odds ratio 3.12), whereas baseline lymphocyte (P=0.011; odds ratio 0.67) and neutrophil counts (P=0.026; odds ratio 0.90) were inversely related to neutropenia occurrence. Sex and treatment intention also significantly influenced chemotherapy-induced neutropenia (P=0.012). The sensitivity and specificity of the model were 63% and 67% respectively, and the positive and negative predictive values were 17% and 94% respectively. Once validated, this model should be a useful tool for clinical decision making.
Figures


Similar articles
-
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20. Eur J Cancer. 2011. PMID: 21095116
-
Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.J Natl Cancer Inst. 2001 Jan 3;93(1):31-8. doi: 10.1093/jnci/93.1.31. J Natl Cancer Inst. 2001. PMID: 11136839 Clinical Trial.
-
Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.Eur J Cancer Care (Engl). 2013 Jul;22(4):513-21. doi: 10.1111/ecc.12057. Epub 2013 Jun 3. Eur J Cancer Care (Engl). 2013. PMID: 23730920
-
Granocyte-colony stimulating factor (G-CSF) has significant efficacy as secondary prophylaxis of chemotherapy-induced neutropenia in patients with solid tumors: results of a prospective study.Anticancer Res. 2013 Jan;33(1):301-7. Anticancer Res. 2013. PMID: 23267161
-
Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.Anticancer Drugs. 2006 Sep;17(8):881-9. doi: 10.1097/01.cad.0000224455.46824.b5. Anticancer Drugs. 2006. PMID: 16940798 Review.
Cited by
-
Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.Medicine (Baltimore). 2016 Mar;95(13):e3240. doi: 10.1097/MD.0000000000003240. Medicine (Baltimore). 2016. PMID: 27043697 Free PMC article.
-
Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score.JNCI Cancer Spectr. 2018 Nov 29;2(4):pky053. doi: 10.1093/jncics/pky053. eCollection 2018 Oct. JNCI Cancer Spectr. 2018. PMID: 31360873 Free PMC article.
-
Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors.BMC Cancer. 2014 Mar 19;14:201. doi: 10.1186/1471-2407-14-201. BMC Cancer. 2014. PMID: 24641830 Free PMC article.
-
Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia.Cancers (Basel). 2025 Mar 30;17(7):1163. doi: 10.3390/cancers17071163. Cancers (Basel). 2025. PMID: 40227705 Free PMC article. Review.
-
The vertebral 3'-deoxy-3'-18F-fluorothymidine uptake predicts the hematological toxicity after systemic chemotherapy in patients with lung cancer.Eur Radiol. 2019 Jul;29(7):3908-3917. doi: 10.1007/s00330-019-06161-4. Epub 2019 Apr 10. Eur Radiol. 2019. PMID: 30972546
References
-
- Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Journal of Cancer. 2006;42:2433–2453. - PubMed
-
- Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA. The predictive value of body protein for chemotherapy-induced toxicity. Cancer. 2000;88:796–803. - PubMed
-
- Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. Journal of Clinical Oncology. 1996;14:636–643. - PubMed
-
- Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. The New England Journal of Medicine. 1995;332:901–906. - PubMed
-
- Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103:1916–1924. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources